CollabRx Announces Receipt Of NASDAQ Notice Of Bid Price Deficiency
Nov 24 14
CollabRx, Inc. announced that it received a letter from the NASDAQ OMX GROUP (Nasdaq) stating that the bid price of the Company's common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Listing Rule 5550(a)(2). The Nasdaq notification letter does not result in the immediate delisting of the Company's common stock, and the stock will continue to trade uninterrupted on the Nasdaq Capital Market under the symbol "CLRX." CollabRx management intends to resolve the situation to allow for continued listing on the Nasdaq Capital Market. CollabRx is provided a grace period of 180-calendar days, or until May 18, 2015, to regain compliance with the minimum bid price requirement. If at any time during the 180-day grace period, the minimum closing bid price per share of the Company's common stock closes at or above $1.00 for a minimum of ten consecutive business days, CLRX will regain compliance and the matter will be closed. In the event the Company does not regain compliance within this grace period, it may be eligible to receive an additional 180-day grace period; provided that CLRX meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and provides written notice of its intention to cure the minimum bid price deficiency during the second 180-day grace period, by effecting a reverse stock split, if necessary. If it appears to the Nasdaq staff that the Company will not be able to cure the deficiency or if the Company is not otherwise eligible for the additional grace period, the Company's common stock will be subject to delisting by Nasdaq.
CollabRx, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended September 30, 2014; Provides Revenue Guidance for the Full Year of 2015
Nov 13 14
CollabRx, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended September 30, 2014. For the quarter, revenue was $176,000 against $251,000 a year ago. Operating loss was $1,039,000 against $872,000 a year ago. Loss before income tax benefit was $1,037,000 against $856,000 a year ago. Loss from continuing operations was $1,016,000 against $836,000 a year ago. Net loss was $1,016,000 against $563,000 a year ago. Basic and diluted net loss per share from continuing operations was $0.35 against $0.43 a year ago. Basic and diluted net loss per share was $0.35 against $0.29 a year ago.
For the six months, revenue was $240,000 against $521,000 a year ago. Operating loss was $2,309,000 against $1,582,000 a year ago. Loss before income tax benefit was $2,300,000 against $1,556,000 a year ago. Loss from continuing operations was $2,264,000 against $1,515,000 a year ago. Net loss was $2,264,000 against $1,360,000 a year ago. Basic and diluted net loss per share from continuing operations was $1.01 against $0.78 a year ago. Basic and diluted net loss per share was $1.01 against $0.70 a year ago.
The company expects to build revenue primarily through the sale of its content in connection with its Genetic Variant Annotation Service. The company expects its revenue to increase as its customers succeed in launching and growing their test sales into a rapidly growing market. In addition, the company expects to report revenue later 2015 in connection with its revenue-sharing agreement for the CancerRx mobile app, developed and marketed in collaboration with Everyday Health's MedPage Today.
Cartagenia Collaborates with CollabRx
Nov 12 14
Cartagenia has collaborated with CollabRx. It was reported that the contract has been signed to offer Cartagenia's customers access to CollabRx's treatment information resources and services. The collaboration offers clinical and pathology laboratories that have adopted Cartagenia's Bench for Oncology software platform for their genetic sequencing analysis and reporting workflow, with the option to access to CollabRx's medical and scientific knowledge, which they can integrate with their own proprietary information to draft physician ready reports. According to the terms of the contract, CollabRx's Genetic Variant Annotation (GVA) Service will be made accessible through Cartagenia's Bench for Oncology software platform. Both firms will promote the partnership by cooperating on marketing initiatives to inform customers of the benefits and advantages of the joint use of each company's products.